← Oncology Approval Tracker

FDA DECISION ·

Ukoniq

umbralisib · TG Therapeutics

Accelerated approvalNew therapyFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on May 31, 2022

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after at least three systemic treatment lines. FDA records list withdrawal of this indication on May 31, 2022.

LAMPGEN ANALYSIS

Why it matters

The follicular lymphoma authorization used a different prior-treatment threshold from the same-day marginal zone lymphoma action.

What research teams should watch

Keep the histology and three-line threshold in the record so separate lymphoma populations can be analyzed.

PRIMARY RECORDS

Sources